外周动脉疾病抗栓治疗进展
Advances in Antithrombotic Therapy for Peripheral Artery Diseases
DOI: 10.12677/ACM.2023.1371596, PDF,   
作者: 陈 媛*, 袁忠明:重庆医科大学附属第二医院老年科,重庆
关键词: 外周动脉疾病抗血小板抗凝利伐沙班Peripheral Arterial Diseases Antiplatelet Anticoagulant Rivaroxaban
摘要: 随着全世界老龄化的进展,外周动脉疾病(peripheral arterial diseases, PAD)的患病率逐渐上升,PAD与糖尿病、高血脂、高血压、吸烟等危险因素密切相关;PAD患者通常有广泛的动脉粥样硬化,PAD进展与其他心血管事件和心血管死亡风险增加相关。因此,外周动脉疾病患者应同时接受非药物和药物二级预防,以降低心血管事件以及其他并发症的风险。目前PAD的治疗方式主要包括生活方式干预、药物治疗与手术治疗,而药物治疗主要包括他汀类药物、血管紧张素转化酶抑制剂以及抗栓治疗等,其中抗栓治疗受到越来越多的关注,本篇综述的重点是介绍PAD的抗血小板和抗凝治疗。无症状PAD不需要抗凝或抗血小板治疗,而对于有缺血性下肢症状(如动脉粥样硬化引起的间歇性跛行或严重肢体缺血)的患者,应使用小剂量阿司匹林或氯吡格雷抗血小板治疗。对于复发性缺血事件风险高、有症状的PAD患者,以及因PAD接受过血管内或开放手术干预的患者,应考虑阿司匹林联合小剂量口服直接抗凝剂(direct oral anticoagulants, NOACs)利伐沙班治疗,并权衡出血风险。
Abstract: With the progress of aging in the world, the prevalence of peripheral artery diseases has gradually increased. PAD is closely related to diabetes, hyperlipidemia, hypertension, smoking and other risk factors. Patients with PAD usually have extensive atherosclerosis. Progression of PAD is associated with an increased risk of other cardiovascular events and cardiovascular death. Therefore, patients with PAD should receive both nonpharmacologic and pharmacologic secondary prevention to re-duce the risk of cardiovascular and other complications. At present, the treatment of PAD mainly includes lifestyle intervention, drug therapy and surgical treatment, and drug therapy mainly in-cludes statins, angiotensin-converting enzyme inhibitors and antithrombotic therapy, among which antithrombotic therapy has received more and more attention. The focus of this review is on an-tiplatelet and anticoagulant therapy for PAD. Asymptomatic PAD does not require anticoagulant or antiplatelet therapy, whereas antiplatelet therapy with low-dose aspirin or clopidogrel should be used in patients with ischemic lower-extremity symptoms, such as intermittent claudication or critical limb ischemia due to atherosclerosis. Aspirin combined with low dose of rivaroxaban should be considered for symptomatic PAD patients with a high risk of recurrent ischemic events, and for those who have received endovascular or open surgical intervention for PAD, and the risk of bleed-ing should be weighed.
文章引用:陈媛, 袁忠明. 外周动脉疾病抗栓治疗进展[J]. 临床医学进展, 2023, 13(7): 11416-11422. https://doi.org/10.12677/ACM.2023.1371596

参考文献

[1] Fowkes, F.G., Aboyans, V., Fowkes, F.J., et al. (2017) Peripheral Artery Disease: Epidemiology and Global Perspec-tives. Nature Reviews Cardiology, 14, 156-170. [Google Scholar] [CrossRef] [PubMed]
[2] Aboyans, V., Ricco, J.-B., Bartelink, M.-L.E.L., et al. (2018) Editor’s Choice—2017 ESC Guidelines on the Diagnosis and Treatment of Pe-ripheral Arterial Diseases, in Collaboration with the European Society for Vascular Surgery (ESVS). European Journal of Vascular and Endovascular Surgery, 55, 305-368. [Google Scholar] [CrossRef] [PubMed]
[3] De Carlo, M., Schlager, O., Mazzolai, L., et al. (2023) Antithrom-botic Therapy Following Revascularization for Chronic Limb-Threatening Ischaemia: A European Survey from the ESC Working Group on Aorta and Peripheral Vascular Diseases. European Heart Journal—Cardiovascular Pharmacother-apy, 9, 201-207. [Google Scholar] [CrossRef] [PubMed]
[4] Fowkes, F.G., Price, J.F., Stewart, M.C., et al. (2010) Aspirin for Prevention of Cardiovascular Events in a General Population Screened for a Low Ankle Brachial Index: A Randomized Controlled Trial. JAMA, 303, 841-848. [Google Scholar] [CrossRef] [PubMed]
[5] Belch, J., Maccuish, A., Campbell, I., et al. (2008) The Prevention of Progression of Arterial Disease and Diabetes (POPADAD) Trial: Factorial Randomised Placebo Controlled Trial of As-pirin and Antioxidants in Patients with Diabetes and Asymptomatic Peripheral Arterial Disease. BMJ, 337, Article No. a1840. [Google Scholar] [CrossRef] [PubMed]
[6] Aboyans, V., Ricco, J.-B., Bartelink, M.-L.E.L., et al. (2018) 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in Collaboration with the European So-ciety for Vascular Surgery (ESVS): Document Covering Atherosclerotic Disease of Extracranial Carotid and Vertebral, Mesenteric, Renal, Upper and Lower Extremity Arteries Endorsed By: The European Stroke Organization (ESO) the Task Force for the Diagnosis and Treatment of Peripheral Arterial Diseases of the European Society of Cardiology (ESC) and of the European Society for Vascular Surgery (ESVS). European Heart Journal, 39, 763-816. [Google Scholar] [CrossRef] [PubMed]
[7] US Preventive Services Task Force (2022) Aspirin Use to Prevent Cardiovascular Disease: US Preventive Services Task Force Recommendation Statement. JAMA, 327, 1577-1584. [Google Scholar] [CrossRef] [PubMed]
[8] CAPRIE Steering Committee (1996) A Randomised, Blinded, Trial of Clopidogrel versus Aspirin in Patients at Risk of Ischaemic Events (CAPRIE). Lancet, 348, 1329-1339. [Google Scholar] [CrossRef
[9] Bhatt, D.L., Fox, K.A., Hacke, W., et al. (2006) Clopidogrel and Aspirin versus Aspirin Alone for the Prevention of Atherothrombotic Events. New England Journal of Medicine, 354, 1706-1717. [Google Scholar] [CrossRef
[10] Burdess, A., Nimmo, A.F., Garden, O.J., et al. (2010) Randomized Controlled Trial of Dual Antiplatelet Therapy in Patients Undergoing Surgery for Critical Limb Is-chemia. Annals of Surgery, 252, 37-42. [Google Scholar] [CrossRef
[11] Zhu, H., Xu, X., Wang, H., et al. (2022) Secondary Preven-tion of Antithrombotic Therapy in Patients with Stable Cardiovascular Disease at High Ischemic Risk: A Network Me-ta-Analysis of Randomized Controlled Trials. Frontiers in Cardiovascular Medicine, 9, Article 1040473. [Google Scholar] [CrossRef] [PubMed]
[12] Jones, W.S., Baumgartner, I., Hiatt, W.R., et al. (2017) Ticagrelor Compared with Clopidogrel in Patients with Prior Lower Extremity Revascularization for Peripheral Artery Disease. Circulation, 135, 241-250. [Google Scholar] [CrossRef
[13] Samoš, M., Fedor, M., Kovář, F., et al. (2016) Ticagrelor: A Safe and Effective Approach for Overcoming Clopidogrel Resistance in Patients with Stent Thrombosis? Blood Coagulation & Fibrinolysis, 27, 117-120. [Google Scholar] [CrossRef
[14] Bonaca, M.P., Bhatt, D.L., Storey, R.F., et al. (2016) Ti-cagrelor for Prevention of Ischemic Events after Myocardial Infarction in Patients with Peripheral Artery Disease. Jour-nal of the American College of Cardiology, 67, 2719-2728. [Google Scholar] [CrossRef] [PubMed]
[15] Abtan, J., Bhatt, D.L., Elbez, Y., et al. (2023) External Applicability of the Effect of Ticagrelor on Health Outcomes in Diabetes Mellitus Patients Intervention Study (THEMIS) Trial: An Analysis of Patients with Diabetes and Coronary Artery Disease in the Reduction of Atherothrombosis for Continued Health (REACH) Registry. International Journal of Cardiology, 370, 51-57. [Google Scholar] [CrossRef] [PubMed]
[16] Miyashita, Y., Saito, S., Miyamoto, A., Iida, O. and Nanto, S. (2011) Cilostazol Increases Skin Perfusion Pressure in Severely Ischemic Limbs. Angiology, 62, 15-17. [Google Scholar] [CrossRef] [PubMed]
[17] O’Donnell, M.E., Badger, S.A., Sharif, M.A., et al. (2009) The Effects of Cilostazol on Exercise-Induced Ischaemia-Reperfusion Injury in Patients with Peripheral Arterial Disease. Eu-ropean Journal of Vascular and Endovascular Surgery, 37, 326-335. [Google Scholar] [CrossRef] [PubMed]
[18] Brown, T., Forster, R.B., Cleanthis, M., et al. (2021) Cilostazol for Intermittent Claudication. Cochrane Database of Systematic Reviews, No. 6, Article No. CD003748. [Google Scholar] [CrossRef
[19] Bonaca, M.P., Gutierrez, J.A., Creager, M.A., et al. (2016) Acute Limb Ischemia and Outcomes with Vorapaxar in Patients with Peripheral Artery Disease: Results from the Trial to Assess the Effects of Vorapaxar in Preventing Heart Attack and Stroke in Patients with Atherosclerosis-Thrombolysis in Myocardial Infarction 50 (TRA2°P-TIMI 50). Circulation, 133, 997-1005. [Google Scholar] [CrossRef
[20] Merlini, P.A., Bauer, K.A., Oltrona, L., et al. (1994) Persistent Activation of Coagulation Mechanism in Unstable Angina and Myocardial Infarction. Circulation, 90, 61-68. [Google Scholar] [CrossRef
[21] Kindell, D.G., Marulanda, K., Caruso, D.M., et al. (2023) In-cidence of Venous Thromboembolism in Patients with Peripheral Arterial Disease after Endovascular Intervention. Jour-nal of Vascular Surgery: Venous and Lymphatic Disorders, 11, 61-69. [Google Scholar] [CrossRef] [PubMed]
[22] Anand, S., Yusuf, S., Xie, C., et al. (2007) Oral Anticoagulant and Antiplatelet Therapy and Peripheral Arterial Disease. New England Journal of Medicine, 357, 217-227. [Google Scholar] [CrossRef
[23] Dutch Bypass Oral anticoagulants or Aspirin (BOA) Study Group (2000) Efficacy of Oral Anticoagulants Compared with Aspirin after Infrainguinal Bypass Surgery (The Dutch Bypass Oral Anticoagulants or Aspirin Study): A Randomised Trial. Lancet, 355, 346-351. [Google Scholar] [CrossRef
[24] Bauersachs, R., Berkowitz, S.D., Brenner, B., Buller, H.R., Decousus, H., et al. (2010) Oral Rivaroxaban for Symptomatic Venous Thromboembolism. New England Journal of Medicine, 363, 2499-2510. [Google Scholar] [CrossRef
[25] Anand, S.S., Bosch, J., Eikelboom, J.W., et al. (2018) Rivaroxaban with or without Aspirin in Patients with Stable Peripheral or Carotid Artery Disease: An International, Randomised, Double-Blind, Placebo-Controlled Trial. Lancet, 391, 219-229. [Google Scholar] [CrossRef
[26] Bonaca, M.P., Bauersachs, R.M., et al. (2020) Rivaroxaban in Peripheral Artery Disease after Revascularization. New England Journal of Medicine, 382, 1994-2004. [Google Scholar] [CrossRef
[27] 陈隽, 周一薇, 李秀娟. 症状性下肢动脉疾病抗栓治疗分析[J]. 临床荟萃, 2021, 36(10): 937-941.